Taha Fatma Aboalsoud, Naeim Hesham, Amoudi Osama, Alnozha Fareed, Almutairi Mansour, Abuelatta Reda
Adult Cardiology Department, Madinah Cardiac Center, Madinah, Saudi Arabia.
Cardiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Struct Heart. 2022 Jun 21;6(3):100043. doi: 10.1016/j.shj.2022.100043. eCollection 2022 Jul.
In specific patients with severe mitral regurgitation (MR), mitral valve (MV) pathology is unique and requires creative transcatheter repair techniques. This study aimed to evaluate the feasibility and safety of a new transcatheter MV repair technique, using occluder devices in symptomatic high-surgical-risk patients with severe MR, either due to MV leaflet (MVL) perforations or due to post-clips residual MR, and to report on their 6-month outcomes.
The study enrolled all high-risk patients with severe MR due to MVL perforations and post-clips residual MR who underwent transcatheter MV repair using occluder devices, from November 2016 to August 2019.
The study enrolled 16 patients; 9 (56.25%) with MVL perforations and 7 (43.75%) with post-MitraClip (Abbott Laboratories, Abbott Park, Illinois) residual MR, with a mean age of 55.75 ± 16.69 years. Mean perforation/jet diameters were 5.75 ± 1.67 and 6.5 ± 1.93 mm, and the mean 3D-vena contracta area was 0.54 ± 0.14 cm. Perforations were crossed retrograde (transaortic in 7 [43.75%] patients and transapical in 2 [12.5%] patients), and post-MitraClip devices residual jets were crossed antegrade (transvenous/transseptal). Six (37.5%) patients required arteriovenous loop formation for device deployment, that was antegrade transvenous/transseptal in 13 (81.25%) patients and retrograde transapical in 3 (18.75%) patients. Devices used were Amplatzer-ASO in 10 (62.5%) patients and Amplatzer-VP-II in 6 (37.5%) patients. Mean procedural and fluoroscopy times were 55.13 ± 16.24 and 16.25 ± 4.03 minutes, respectively. Patients passed successfully, without MV gradient change or device-related complications.
Transcatheter MV repair of MVL perforations/post-clips residual MR is a new, feasible, and safe technique for high-surgical-risk patients.
在特定的严重二尖瓣反流(MR)患者中,二尖瓣(MV)病变具有独特性,需要创新的经导管修复技术。本研究旨在评估一种新的经导管MV修复技术的可行性和安全性,该技术使用封堵器装置治疗有症状的高手术风险严重MR患者,这些患者的病因是二尖瓣叶(MVL)穿孔或夹闭术后残留MR,并报告其6个月的结局。
本研究纳入了2016年11月至2019年8月期间所有因MVL穿孔和夹闭术后残留MR而接受经导管MV修复并使用封堵器装置的高风险患者。
本研究共纳入16例患者;9例(56.25%)为MVL穿孔,7例(43.75%)为MitraClip(雅培实验室,伊利诺伊州雅培公园)夹闭术后残留MR,平均年龄为55.75±16.69岁。穿孔/射流平均直径分别为5.75±1.67和6.5±1.93mm,平均三维缩流颈面积为0.54±0.14cm²。穿孔采用逆行穿过(7例[43.75%]经主动脉,2例[12.5%]经心尖),MitraClip装置术后残留射流采用顺行穿过(经静脉/经房间隔)。6例(37.5%)患者需要形成动静脉环以部署装置,其中13例(81.25%)患者采用顺行经静脉/经房间隔,3例(18.75%)患者采用逆行经心尖。使用的装置为10例(62.5%)患者使用Amplatzer-ASO,6例(37.5%)患者使用Amplatzer-VP-II。平均手术时间和透视时间分别为55.13±16.24分钟和16.25±4.03分钟。患者均顺利通过,未出现MV梯度变化或与装置相关的并发症。
经导管修复MVL穿孔/夹闭术后残留MR对高手术风险患者是一种新的、可行且安全的技术。